Genetic Technologies (ASX:GTG) Stock Based Compensation: A$0.00 Mil (TTM As of Jun. 2024)


What is Genetic Technologies Stock Based Compensation?

Genetic Technologies ASX:GTG Stock Based Compensation is A$0.00 Mil as of Jun. 2024.

Genetic Technologies's Stock Based Compensation for the three months ended in Jun. 2024 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00 Mil.

Genetic Technologies Stock Based Compensation Related Terms

Genetic Technologies Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Stock Based Compensation Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Technologies Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Stock Based Compensation of A$0.00 Mil mean?
Genetic Technologies (ASX:GTG) has a Stock Based Compensation of A$0.00 Mil as of Jun. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Genetic Technologies and its competitors.
Is Genetic Technologies' Stock Based Compensation too high?
Genetic Technologies' current Stock Based Compensation is A$0.00 Mil.
How does Genetic Technologies' Stock Based Compensation compare to LDDD and NOTV?
Genetic Technologies' Stock Based Compensation of A$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Genetic Technologies and its competitors. Genetic Technologies's current Stock Based Compensation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Stock Based Compensation of A$0.00 Mil. The current Stock Based Compensation is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Stock Based Compensation is A$0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.